Shanmuga Hospital Limited FY26 Profit Holds Steady at ₹4.21 Crore

Shanmuga Hospital Limited reported FY26 net profit of ₹4.21 crore, marginally above ₹4.21 crore in FY25, while revenue from operations fell 0.9% to ₹47.44 crore. The board approved the audited results for the half year and year ended March 31, 2026, with the statutory auditor issuing an unmodified opinion.

What did Shanmuga Hospital report for FY26?

Shanmuga Hospital reported revenue from operations of ₹47.44 crore for the year ended March 31, 2026, compared with ₹47.85 crore in FY25. Profit after tax was ₹4.21 crore, against ₹4.21 crore a year earlier, showing that the company broadly maintained its annual profit despite a modest decline in operating revenue.

Total income was ₹48.06 crore, almost unchanged from ₹48.09 crore in the preceding year. Other income rose to ₹0.63 crore from ₹0.23 crore, while total expenses were stable at ₹42.39 crore. Profit before tax stood at ₹5.67 crore, marginally lower than ₹5.69 crore in FY25.

The audited results also show different performance across the two halves of FY26. Revenue from operations was ₹24.62 crore in the first half and ₹22.82 crore in the second half. Net profit was ₹2.01 crore in H1 FY26 and ₹2.20 crore in H2 FY26.

How did the audited results compare with FY25?

Shanmuga Hospital's FY26 operating revenue was lower by ₹0.42 crore from FY25, while total income remained broadly flat because of the increase in other income. Total expenses also remained nearly unchanged, which helped preserve the company's profit after tax for the year.

The annual net-profit increase was ₹0.004 crore, or about ₹0.39 lakh, making the year-on-year movement effectively flat. The results therefore indicate stable reported profitability rather than a material expansion in earnings during FY26.

For the half year ended March 31, 2026, revenue from operations was ₹22.82 crore, compared with ₹23.23 crore in H2 FY25. However, H2 FY26 net profit rose to ₹2.20 crore from ₹1.81 crore in the comparable prior-year half. Other income in H2 FY26 was ₹0.53 crore, against ₹0.03 crore in H2 FY25.

Basic and diluted earnings per share for FY26 were ₹3.09, compared with ₹4.03 in FY25. The reported half-year EPS figures were not annualised. Investors assessing per-share performance should distinguish between the broadly stable annual profit and the lower EPS reported for the full year.

What did the board and auditor approve?

Shanmuga Hospital's board approved the audited financial results for the half year and full year ended March 31, 2026, at its meeting held on May 11, 2026. The approval was disclosed under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The statutory audit was conducted by M/s PPN & Company, Chartered Accountants, Chennai, with firm registration number 013623S. The auditor issued an unmodified audit opinion on the annual audited financial results, meaning the audit report did not contain a qualification, adverse opinion, or disclaimer.

The FY26 approval followed the release of unaudited financial results for the half year ended September 30, 2025, on November 12, 2025. The audited annual results provide the final reported figures for FY26 after the statutory audit process.

The company has also disclosed a board meeting scheduled for November 12, 2026, to consider unaudited results for the quarter and half year ended September 30, 2026. The agenda includes consideration of a first interim dividend for FY2026-27, if any.

What do the FY26 results mean for investors and operations?

Shanmuga Hospital's FY26 results show a business where reported annual profit was retained despite lower revenue from operations. Stable total expenses and higher other income contributed to this outcome, while profit before tax was slightly below the prior year's level.

For investors, the key financial comparison is between the 0.9% decline in revenue from operations and the largely unchanged profit after tax. The available disclosures do not provide a detailed operational explanation for the revenue movement, so the reported figures do not establish the specific drivers behind the change.

The June 2026 quarter, disclosed separately, showed sales of ₹11.87 crore and net profit of ₹0.99 crore. This compared with sales of ₹11.48 crore and net profit of ₹0.95 crore in the June 2025 quarter. The company is due to place its September 2026 quarter and half-year results before the board on November 12, 2026.

The trading window for company securities was closed from October 1, 2026, until 48 hours after the announcement of the September 2026 results, in line with SEBI insider-trading regulations. The proposed consideration of an interim dividend is an additional item on the board agenda, but no dividend amount has been disclosed.

Conclusion

Shanmuga Hospital completed FY26 with ₹47.44 crore of revenue from operations and ₹4.21 crore of net profit. Revenue was modestly lower than FY25, but stable expenses and higher other income kept annual profit almost unchanged. The unmodified audit opinion provides the formal audit conclusion on the results approved by the board.

The next disclosed event is the November 12, 2026 board meeting for the September 2026 quarter and half-year results. Investors will watch the updated revenue and profitability figures, along with the board's decision on a first interim dividend for FY2026-27, if any.